biosimilar

REYKJAVIK, Iceland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of…

Dr. Reddy’s Laboratories shares gained on Monday in the backdrop of the drugmaker announcing successful completion of a phase-1 study of its proposed biosimilar of tocilizumab for use in the…

Hukyndra® (adalimumab) launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in…

New York, United States, Nov. 23, 2022 (GLOBE NEWSWIRE) -- A biosimilar is a generic version of a well-known biologic drug. Biologic drugs are medicines made from living things like…

The FDA approved the second interchangeable biosimilar insulin product, Eli Lilly's insulin…

PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar…

Increases availability of cost-effective high-concentration low-volume adalimumab in AustraliaFirst approved biosimilar from the partnership with Cipla, which also includes four other…

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application…

SB15, a proposed biosimilar to EYLEA, showed equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics profile to reference aflibercept in the Phase 3 study interim…